Dataset opportunity
Promocell — 可下载数据资产机会
Promocell 持有的可下载大型数据资产，可用于微调和预训练。
Score
70.8
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
64%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球细胞培养市场在 2025 年的价值为 193.9 亿美元，预计将以 13.14% 的复合年增长率增长。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
可下载数据资产
Modality
表格
Sector
医疗保健
Volume
大型
Freshness
定期
Rarity
中等
Accessibility
受限
Legal
公司所有 — GDPR 敏感（PII 审查）
Buyer persona
领域 LLM 构建者和垂直人工智能初创公司
PromoCell 的可下载资产是一个表格数据集，提供了人类原代细胞的综合视图，包括医疗记录、工业数据（如批次特定的生物样本行为）和监管详细信息。这些丰富、结构化的数据将供体元数据与专有的细胞培养配方和结果联系起来，非常适合用于旨在预测生物学和加速药物发现的复杂人工智能模型的微调。
该数据是全球细胞培养市场的关键资产，该市场在 2025 年的价值为193.9 亿美元，预计将以 13.14% 的复合年增长率增长。虽然访问受 GDPR 和商业秘密谈判的约束，但与实体样本深度关联的稀有数据使其极具价值。它为寻求在此高增长市场中进行创新的由人工智能驱动的制药公司提供了独特的竞争优势。⚠ 尽职调查（有价值的数据，可协商访问）：人类供体元数据受严格的 GDPR 和道德约束；数据与实体生物样本和批号深度关联；专有的细胞培养配方可能受商业秘密保护 · 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Promocell 持有一个有价值的多模态数据集，涵盖了细胞培养生命周期，从细粒度的供体医疗记录到实时工业过程监控和GMP 级监管文件。该资产是领域 LLM 构建者和垂直人工智能初创公司寻求微调模型以适应快速增长的 190 亿美元全球细胞培养市场的强大资源。获取这些数据为开发用于生物制造优化、预测生物学和自动化监管合规的专业人工智能提供了直接途径，从而建立了显著的竞争壁垒。
See dimension details ↓- Dataset Specificity90
主导的“下载”，医疗保健行业，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity58
专有领域数据（开放会降低稀有度）
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume82
8 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness62
API/开放（当前）
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
适用于微调
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
人工智能买家需求由细胞培养市场 13.14% 的快速复合年增长率驱动，这产生了对高质量专有数据以微调生物制药研发预测模型的需求。
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility14
开放/API 访问
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility48
中等难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength86
4 种证据类型，8 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=公司所有，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 数据胃口信号（0 类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit92
✓ 良好目标 — PromoCell 是一个强有力的目标，因为它生产和销售实体细胞培养产品，产生大量有价值的、小众的研发和质量控制数据作为副产品，而它似乎并未将其作为核心业务进行货币化。问题：该公司已被评为德国最具吸引力的中型公司之一，这表明它可能处于中小型企业的较大一端，但可能；数据来源于人类组织供体，这带来了严格的隐私和道德义务（例如 GDPR），公司对此非常清楚；该公司提供“延长使用权”以商业化应用其细胞，这是一项服务而非原始数据产品。
- Deep Qualification90
✓ 通过 — PromoCell 是一个强大的数据持有者候选者。它销售人类细胞和培养基，产生有价值的副产品数据集，包括供体元数据（包括 HLA 分型）、细胞行为和配方性能，这对于药物发现中的人工智能高度相关。然而，数据受到严格的 GDPR 和道德约束，其商业再利用需要协商特定的“延长使用权”许可。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Downloads / exports
证据指向可下载的应用说明，提供结构化的表格数据，关于用于在既定细胞培养程序上训练模型的技术协议。
Medical records / imaging
该资产包含详细的医疗记录，包括特定的供体信息，如年龄、性别和 HLA 分型，这对于开发预测基于患者人口统计学结果的人工智能至关重要。
Industrial data
持有者通过对细胞增殖和代谢活动的自动化、实时分析生成时间序列工业数据，这是旨在优化生物制造过程的人工智能模型的关键输入。
Regulatory records
该数据集包含基于数十年的专业知识和遵守GMP 级标准的文本信息监管信息，这对于将语言模型微调到生物制药合规性的细微差别至关重要。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Promocell Downloadable Data — a Large downloadable data asset (Tabular modality) in the healthcare domain. Primary AI use-case: Fine Tuning. Market signal: Global cell culture market was valued at $19.39 billion in 2025, projected to grow at a 13.14% CAGR (source: Fortune Business Insights).. Investment score 70.8/100 (confidence 0.64). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Deutsche Pensexpert — 监管记录数据集机会
View opportunity →其他Skedaddlewildlife — 检查报告数据集机会
View opportunity →其他Beaverpest — 检验报告数据集机会
View opportunity →